Cardiovascular disease prevention

size and potential impact on the target population's health. • Impact on inequalities in health between different groups of the population. • Equality and diversity legislation. • Ethical issues and social value judgements. • Cost effectiveness (for the NHS and other public sector organisations). • Balance of harms and benefits. • Ease of implementation and any anticipated changes in practice. Where possible, recommendations were linked to evidence statements (see appendix C). Where a recommendation was inferred from the evidence, this was indicated by the reference 'IDE' (inference derived from the evidence). The draft guidance, including the recommendations, was released for consultation in October 2009. At its meeting in December 2009, the PDG amended the guidance in light of comments from stakeholders and experts and the fieldwork. The guidance was signed off by the NICE Guidance Executive in May 2010. Appendix C: The evidence This appendix lists the evidence statements from four reviews, a cost-effectiveness review and a primary research study provided by external contractors (see appendix A) and links them to the relevant recommendations. (See appendix B for the key to quality assessments.) The evidence statements are presented here without references, these can be found in the full reviews (see
